Engineering CAR T Cells to Resist Tumor Immune Suppression
CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models
False
CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
March 27, 2026
2 min read
New study indicates that mRNA therapy can restore fertility and sperm production in previously infertile mice
March 16, 2026
2 min read
The first-in-human ATLAS trial will test PRAME-targeting CRISPR T cells in advanced cancers
March 13, 2026
2 min read
Modified APOBEC3G editors improve CRISPR base-editing specificity and reduce bystander mutations in human cells
March 9, 2026
2 min read
CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models
False
Affiliations:
Specialties:
Areas of Expertise: